This kit utilizes KeyTec® TR-FRET technology for high‑throughput screening, enabling accurate measurement of IL17FF/IL17RA protein‑protein interactions and assessment of the activities of small‑molecule inhibitors, peptides, and antibody‑blocking agents.
This kit utilizes KeyTec® TR-FRET technology for high‑throughput screening, enabling accurate measurement of IL17AA/IL17RA protein‑protein interactions and assessment of the activities of small‑molecule inhibitors, peptides, and antibody‑blocking agents.
This kit provides a robust TR-FRET-based assay for rapidly identifying blockers of the IL6/IL6R protein–protein interaction. It uses fluorescent donor–acceptor pairs tagged to IL6 and IL6R, respectively; binding brings the tags close enough to generate a FRET signal, while inhibitors reduce this signal, enabling straightforward quantification and high-throughput screening.
This kit offers a TR-FRET-based platform for rapid, high-throughput screening of blockers targeting the IL12/IL12R-β1 protein–protein interaction. The assay relies on fluorescent donor–acceptor pairs conjugated to IL12 and IL12R-β1, respectively; binding brings the pair into proximity to generate a FRET signal, while inhibitory compounds reduce this signal.
This kit provides a TR-FRET-based assay for rapid, high-throughput screening of blockers targeting the IL23/IL23R protein–protein interaction. The assay employs fluorescent donor–acceptor pairs conjugated to IL23 and IL23R, respectively; binding brings the pair into close proximity to generate a FRET signal, while inhibitory compounds reduce this signal.
This kit offers a TR-FRET-based assay for rapid, high-throughput screening of blockers targeting the IL23/IL12R-β1 protein–protein interaction. The assay uses fluorescent donor–acceptor pairs conjugated to IL23 and IL12R-β1, respectively; binding brings the pair into proximity to generate a FRET signal, while inhibitory compounds reduce this signal.
The KeyTec® TR‑FRET Human IL‑17AF/IL‑17RA Binding Assay Kit provides a rapid, accurate, and homogeneous method for high‑throughput screening of blockers of the IL‑17AF–IL‑17RA interaction. This format is ideal for evaluating small molecules, peptides, and antibodies as potential IL‑17 pathway modulators.